doi:10.3969/j.issn.1004-583X.2025.07.012

Abstract

CLC Number:

R562.25

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.07.012

http://www.lchc.cn/EN/Y2025/V40/I7/653

Figures/Tables 3

References 53

[1]	Varricchi G, Ferri S, Pepys J, et al. Biologics and airway remodeling in severe asthma[J]. Allergy, 2022, 77(12):3538-3552. doi: 10.1111/all.15473 pmid: 35950646
[2]	Hammad H, Lambrecht BN. The basic immunology of asthma[J]. Cell, 2021, 184(9):2521-2522. doi: 10.1016/j.cell.2021.04.019 pmid: 33930297
[3]	史梦迪, 王超, 王钇杰, 等. 中医药调控支气管哮喘相关信号通路研究进展[J]. 中成药, 2024, 46(10):3352-3358.
[4]	王珏, 刘琪, 张潇予, 等. 基于IL-4/JAK1/STAT6信号通路影响巨噬细胞M2极化探讨培元定喘汤治疗哮喘气道炎症的作用机制[J]. 中华中医药杂志, 2024, 39(8):4312-4316.
[5]	Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: From bench to clinic[J]. Signal Transduct Target Ther, 2021, 6(1):402.
[6]	Xue C, Yao Q, Gu X, et al. Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer[J]. Signal Transduct Target Ther, 2023, 8(1):204.
[7]	Owen KL, Brockwell NK, Parker BS. JAK-STAT Signaling: A double-edged sword of immune regulation and cancer progression[J]. Cancers (Basel), 2019, 11(12):2002.
[8]	Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects[J]. Drugs, 2017, 77(8):939.
[9]	Arimoto KI, Löchte S, Stoner SA, et al. STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling[J]. Nat Struct Mol Biol, 2017, 24(3):279-289.
[10]	Yan Z, Gibson SA, Buckley JA, et al. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases[J]. Clin Immunol, 2018, 189:4-13. doi: S1521-6616(16)30449-1 pmid: 27713030
[11]	Gao Q, Liang X, Shaikh AS, et al. JAK/STAT signal transduction: Promising attractive targets for immune, inflammatory and hematopoietic diseases[J]. Curr Drug Targets, 2018, 19(5):487-500. doi: 10.2174/1389450117666161207163054 pmid: 27928945
[12]	Linossi EM, Li K, Veggiani G, et al. Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands[J]. Nat Commun, 2023, 14(1):7951. doi: 10.1038/s41467-023-42706-4 pmid: 38040684
[13]	Durham GA, Williams JJL, Nasim MT, et al. Targeting SOCS proteins to control JAK-STAT signalling in disease[J]. Trends Pharmacol Sci, 2019, 40(5):298-308.
[14]	Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells[J]. Cell Commun Signal, 2017, 15(1):23. doi: 10.1186/s12964-017-0177-y pmid: 28637459
[15]	Pike KA, Tremblay ML. Protein tyrosine phosphatases: Regulators of CD4 T cells in inflammatory bowel disease[J]. Front Immunol, 2018, 9:2504. doi: 10.3389/fimmu.2018.02504 pmid: 30429852
[16]	Badi YE, Salcman B, Taylor A, et al. IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma[J]. Allergy, 2023, 78(1):156-167.
[17]	杨艳, 薛征. TLR4基因敲除对哮喘小鼠气道炎症的影响[J]. 中国免疫学杂志, 2021, 37(24):2945-2949.
[18]	Athari SS. Targeting cell signaling in allergic asthma[J]. Signal Transduct Target Ther, 2019, 4:45.
[19]	Chen X, Yue R, Li X, et al. Surfactant protein A modulates the activities of the JAK/STAT pathway in suppressing Th1 and Th17 polarization in murine OVA-induced allergic asthma[J]. Lab Invest, 2021, 101(9):1176-1185. doi: 10.1038/s41374-021-00618-1 pmid: 34108631
[20]	Golebski K, Layhadi JA, Sahiner U, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response[J]. Immunity, 2021, 54(2):291-307. doi: 10.1016/j.immuni.2020.12.013 pmid: 33450188
[21]	Karpathiou G, Papoudou-Bai A, Ferrand E, et al. STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology[J]. Pathol Res Pract, 2021, 223:153477.
[22]	Yang X, Wang F. The effect of astragaloside IV on JAK2-STAT6 signalling pathway in mouse model of ovalbumin-induced asthma[J]. J Anim Physiol Anim Nutr (Berl), 2019, 103(5):1578-1584. doi: 10.1111/jpn.13114 pmid: 31148265
[23]	Luo W, Hu J, Xu W, et al. Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma[J]. Front Immunol, 2022, 13:974066.
[24]	Escamilla-Gil JM, Fernandez-Nieto M, Acevedo N. Understanding the cellular sources of the Fractional Exhaled Nitric Oxide (FeNO) and its role as a biomarker of type 2 inflammation in asthma[J]. Biomed Res Int, 2022, 2022:5753524.
[25]	Yuan F, Zhang Q, Dong H, et al. Effects of des-acyl ghrelin on insulin sensitivity and macrophage polarization in adipose tissue[J]. J Transl Int Med, 2021, 9(2):84-97. doi: 10.2478/jtim-2021-0025 pmid: 34497748
[26]	Sergi C, Shen F, Liu SM. Insulin/IGF-1R, SIRT1, and FOXOs pathways-an intriguing interaction platform for bone and osteosarcoma[J]. Front Endocrinol (Lausanne), 2019, 10:93.
[27]	Nikolskii AA, Shilovskiy IP, Barvinskaia ED, et al. Role of STAT3 transcription factor in pathogenesis of bronchial asthma[J]. Biochemistry (Mosc), 2021, 86(11):1489-1501. doi: 10.1134/S0006297921110122 pmid: 34906042
[28]	Jaramillo AM, Vladar EK, Holguin F, et al. Emerging cell and molecular targets for treating mucus hypersecretion in asthma[J]. Allergol Int, 2024, 73(3):375-381. doi: 10.1016/j.alit.2024.04.002 pmid: 38692992
[29]	Singh G, Acharya S, Shukla S, et al. Muco-Obstructive Lung Disease: A systematic review[J]. Cureus, 2023, 15(10):e46866.
[30]	Wang X, Xu C, Ji J, et al. IL-4/IL-13 upregulates sonic hedgehog expression to induce allergic airway epithelial remodeling[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 318(5):L888-L899.
[31]	张积涛, 王永军, 傅雪茜, 等. 褪黑素对心力衰竭大鼠JAK1/STAT3信号通路的调节作用[J]. 免疫学杂志, 2022, 38(4):332-339.
[32]	钟秀君, 顾文燕, 徐威, 等. 蠲饮泄肺方通过SOCS1负调控JAK1/STAT1通路对气道黏液高分泌的作用[J]. 上海中医药杂志, 2018, 52(9):69-73.
[33]	Ding F, Liu B, Zou W, et al. LPS exposure in early life protects against mucus hypersecretion in ovalbumin-induced asthma by down-regulation of the IL-13 and JAK-STAT6 pathways[J]. Cell Physiol Biochem, 2018, 46(3):1263-1274. doi: 10.1159/000489109 pmid: 29680833
[34]	屯妮萨古丽·艾买提江, 李改茹. 免疫细胞在支气管哮喘发病机制中的作用研究进展[J]. 细胞与分子免疫学杂志, 2024, 40(5):465-471.
[35]	Jie XL, Luo ZR, Yu J, et al. Pi-Pa-Run-Fei-Tang alleviates lung injury by modulating IL-6/JAK2/STAT3/IL-17 and PI3K/AKT/NF-κB signaling pathway and balancing Th17 and Treg in murine model of OVA-induced asthma[J]. J Ethnopharmacol, 2023, 317:116719.
[36]	刘洁, 邓亚胜, 尹蔚萍, 等. 中医药靶向M1/M2巨噬细胞极化平衡治疗支气管哮喘研究进展[J/OL]. 中国实验方剂学杂志, 1-15[2025-02-27].
[37]	Oo A, Teoh BT, Sam SS, et al. Baicalein and baicalin as Zika virus inhibitors[J]. Arch Virol, 2019, 164(2):585-593. doi: 10.1007/s00705-018-4083-4 pmid: 30392049
[38]	Huang Q, Han L, Lv R, et al. Magnolol exerts anti-asthmatic effects by regulating Janus kinase-signal transduction and activation of transcription and Notch signaling pathways and modulating Th1/Th2/Th17 cytokines in ovalbumin-sensitized asthmatic mice[J]. Korean J Physiol Pharmacol, 2019, 23(4):251-261.
[39]	余保, 申严, 卓宋明. 黄芩素对哮喘小鼠气道平滑肌细胞增殖、迁移及JAK/STAT通路的影响[J]. 广西医科大学学报, 2021, 38(9):1692-1697.
[40]	Leis K, Gałᶏzka P, Kazik J, et al. Resveratrol in the treatment of asthma based on an animal model[J]. Postepy Dermatol Alergol, 2022, 39(3):433-438.
[41]	武莉莉, 张敏, 陈延伟, 等. 白藜芦醇对哮喘模型鼠气道炎症及JAK-STAT6信号通路的影响[J]. 广东医学, 2022, 43(6):692-696.
[42]	崔治家, 马艳珠, 张小荣, 等. 川贝母化学成分和药理作用研究进展及质量标志物的预测分析[J]. 中草药, 2021, 52(9):2768-2784.
[43]	侯从岭, 芦晓帆, 雷小婷, 等. 川贝母对卵清蛋白致敏哮喘小鼠的作用及其机制[J]. 解放军医学杂志, 2022, 47(8):789-794.
[44]	李贵明, 李燕. 人参皂苷药理作用研究现状[J]. 中国临床药理学杂志, 2020, 36(8):1024-1027.
[45]	Lai Y, Tan Q, Xv S, et al. Ginsenoside Rb1 alleviates alcohol-induced liver injury by inhibiting steatosis, oxidative stress, and inflammation[J]. Front Pharmacol, 2021, 12:616409.
[46]	刘曦, 罗晓松, 孙涛. 人参皂苷Rb1对过敏性哮喘大鼠炎症反应、免疫功能及JAK2/STAT3信号通路的影响[J]. 中国老年学杂志, 2024, 44(2):367-371.
[47]	秦聪聪, 张诗敏, 王亚男, 等. 马鞭草的炮制历史沿革、化学成分及药理作用研究进展[J]. 世界中医药, 2024, 19(21):3326-3340.
[48]	秦晓颖, 陈文静, 刘玉萍, 等. 和厚朴酚与厚朴酚治疗免疫紊乱疾病及其免疫调控作用研究进展[J]. 中草药, 2024, 55(24):8602-8612.
[49]	吕川, 朱慧志, 刘向国, 等. 基于IL-6/JAK2/STAT3信号轴研究阳和平喘颗粒调控哮喘大鼠气道重塑作用机制[J]. 海南医学院学报, 2024, 30(1):15-20+28.
[50]	郭超, 童希洋, 秦伟伟, 等. 苏黄止咳胶囊改善哮喘豚鼠气道重塑的作用及其机制[J]. 中成药, 2021, 43(4):893-901.
[51]	叶勇, 赵凡, 贺思雨, 等. 基于JAK-STAT信号通路探究降气平喘汤干预支气管哮喘的作用机制[J]. 湖南中医药大学学报, 2024, 44(10):1754-1763.
[52]	Wu Z, Luo Z, Sun W, et al. Integrating network pharmacology and experimental validation to elucidate the mechanism of jiegeng decoction in improving allergic asthma[J]. ACS Omega, 2023, 8(50):48081-48090. doi: 10.1021/acsomega.3c06914 pmid: 38144091
[53]	柳京池, 徐丽. 中药靶向调控TLR4/NF-κB信号通路治疗哮喘的研究进展[J/OL]. 中药材, 2024, (11):2913-2921.

药物类别	中药单体	来源	试验对象	作用靶点
黄酮类化合物	黄芩素	黄芩	SPF级BALB/c小鼠	p-JAK2、JAK2、p-STAT、STAT3
多酚类化合物	白藜芦醇	虎杖、射干	SPF级BALB/c小鼠	JAK/STAT6
生物碱类化合物	川贝母	百合科草本植物	SPF级BALB/c小鼠	JAK3/STAT6
苷类化合物	人参皂苷Rb1	人参	SD大鼠	JAK2/STAT3
	马鞭草苷	马鞭草	SD大鼠	p-JAK3/JAK3、p-STAT6/STAT6
其他类化合物	厚朴酚	干燥根皮、干皮及枝皮	BALB/c小鼠	JAK1、JAK2、JAK3、STAT1、STAT3、STAT6、p-STAT1、p-STAT3、p-STAT6

药物类别	中药单体	来源	试验对象	作用靶点
黄酮类化合物	黄芩素	黄芩	SPF级BALB/c小鼠	p-JAK2、JAK2、p-STAT、STAT3
多酚类化合物	白藜芦醇	虎杖、射干	SPF级BALB/c小鼠	JAK/STAT6
生物碱类化合物	川贝母	百合科草本植物	SPF级BALB/c小鼠	JAK3/STAT6
苷类化合物	人参皂苷Rb1	人参	SD大鼠	JAK2/STAT3
	马鞭草苷	马鞭草	SD大鼠	p-JAK3/JAK3、p-STAT6/STAT6
其他类化合物	厚朴酚	干燥根皮、干皮及枝皮	BALB/c小鼠	JAK1、JAK2、JAK3、STAT1、STAT3、STAT6、p-STAT1、p-STAT3、p-STAT6

中药复方	组成	试验对象	作用靶点
培元定喘汤	炙甘草枸杞子、蜜款冬花、太子参、蜜百部、炙麻黄、淫羊藿、地龙、五味子、黄芪	C57BL/6小鼠	IL-4/JAK1/STAT6
阳和平喘颗粒	五味子、熟地黄、葶苈子、巴戟天、桔梗、白芥子、旋覆花、麻黄、当归	SD大鼠	IL-6/JAK2/STAT3
苏黄止咳胶囊	蜜炙枇杷叶、炒紫苏子、紫苏叶、蜜炙麻黄、蝉蜕、五味子、地龙、炒牛蒡子、前胡	普通级豚鼠	p-JAK2/JAK2、p-STAT3/STAT3
降气平喘汤	桑白皮、地骨皮、葶苈子、紫苏子、款冬花、紫菀、瓜蒌皮、甜叶菊、麻黄、杏仁、白果、桔梗、甘草	SD雄性大鼠	JAK1、JAK2、p-STAT3/STAT3、p-STAT5/STAT5
桔梗汤	桔梗、甘草	BALB/c小鼠	JAK1、STAT6、p-JAK1、p-STAT6

中药复方	组成	试验对象	作用靶点
培元定喘汤	炙甘草枸杞子、蜜款冬花、太子参、蜜百部、炙麻黄、淫羊藿、地龙、五味子、黄芪	C57BL/6小鼠	IL-4/JAK1/STAT6
阳和平喘颗粒	五味子、熟地黄、葶苈子、巴戟天、桔梗、白芥子、旋覆花、麻黄、当归	SD大鼠	IL-6/JAK2/STAT3
苏黄止咳胶囊	蜜炙枇杷叶、炒紫苏子、紫苏叶、蜜炙麻黄、蝉蜕、五味子、地龙、炒牛蒡子、前胡	普通级豚鼠	p-JAK2/JAK2、p-STAT3/STAT3
降气平喘汤	桑白皮、地骨皮、葶苈子、紫苏子、款冬花、紫菀、瓜蒌皮、甜叶菊、麻黄、杏仁、白果、桔梗、甘草	SD雄性大鼠	JAK1、JAK2、p-STAT3/STAT3、p-STAT5/STAT5
桔梗汤	桔梗、甘草	BALB/c小鼠	JAK1、STAT6、p-JAK1、p-STAT6

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 53

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(1): 88-91.
[2]	Ruan Junwen, Zhou Jianrong, Liu Weiyou, Yuan Xiaoliang, Yan Hao. Meta-analysis of the efficacy and safety of dupilumab on the treatment of bronchial asthma [J]. Clinical Focus, 2023, 38(10): 869-877.
[3]	Fu Qun, Guo Di, Zhao Wenfei. VEGF, ICAM-1, IL-13, FeNO level of induced sputum on asthma, asthma-copd overlap, and chronic obstructive pulmonary disease in patients: clinical changes and significance [J]. Clinical Focus, 2021, 36(6): 513-516.
[4]	Zhang Jin;Song Ning;Gao Naifen;Yang Congli;LV Huoqiang;DU Bo-ying. Influence of montelukast combined with budesonide on serum transforming growth factor beta 1 and serum amyloid A in children with cough variant asthma [J]. Clinical Focus, 2015, 30(11): 1273-1.27513e+007.
[5]	Lü Hong;Qian Xingjia;Huang Jianan. Change of serum eotaxin, IL-17 and periostin levels in asthma patients and significance [J]. Clinical Focus, 2015, 30(10): 1163-1166.
[6]	. @@ [J]. Clinical Focus, 2015, 30(8): 940-942.
[7]	Li Jing;Wang Liang;Yang Hongshen;Li Yamei;Hou Hongwei;Li Xianglan;Zhang Congyao;Li Yujing. Effect of doxycycline on airway inflammation and remodeling in asthmatic rats [J]. Clinical Focus, 2015, 30(4): 416-420.
[8]	. [J]. CLINICAL FOCUS, 2013, 28(10): 1168-1170.
[9]	. [J]. CLINICAL FOCUS, 2013, 28(8): 947-950.
[10]	FENG Jian;ZHANG Xu-hua;GAO Yan;ZHANG Sheng-shan;LI Yin-huan. Relationships between gender,age,and airway hyperresponsiveness in 251 suspected asthmatic patients [J]. CLINICAL FOCUS, 2013, 28(7): 732-734737.
[11]	. [J]. CLINICAL FOCUS, 2013, 28(6): 696-699.
[12]	. [J]. Clinical Focus, 2012, 27(19): 1743-1745.
[13]	. [J]. Clinical Focus, 2012, 27(17): 1525-1527.
[14]	CUI Jia-li;WU Hong-qi;LIU Xiu-zhen;XU Qing. Study on cysteinyl leukotriene receptor antagonist depressing airway remodeling in asthma model [J]. Clinical Focus, 2012, 27(13): 1133-0.
[15]	. [J]. Clinical Focus, 2012, 27(9): 782-783.